<DOC>
	<DOCNO>NCT02366637</DOCNO>
	<brief_summary>This study propose evaluate safety efficacy PF-03715455 subject moderate severe Chronic Obstructive Pulmonary Disorder .</brief_summary>
	<brief_title>An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Female subject nonchildbearing potential male subject age 40 80 year , inclusive Subjects diagnosis , least 6 month , moderate severe COPD meet criterion Stage IIIII disease Subjects must smoke history least 10 packyears Current evidence history within previous 6 month clinically significant disease ( COPD ) abnormality opinion Investigator would put subject risk would compromise quality study data A COPD exacerbation require treatment oral steroid hospitalization treatment COPD within 3 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Sputum</keyword>
</DOC>